Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07075406 · ClinicalTrials.gov registry record

A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept

A clinical trial, sponsored by Bristol-Myers Squibb.

Completed
Registry status
250
Enrollment target

NCT07075406 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 250 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07075406 has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
250 participants
Enrollment target

Study Summary

The purpose of this study is to understand the treatment use of luspatercept in adults diagnosed with lower-risk myelodysplastic syndromes

Interventions

  • DRUG Luspatercept

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2024-11-01
Est. Completion 2025-08-01

Sponsor

Bristol-Myers Squibb

1,025 total trials

What the Registry Record Tells You About NCT07075406

The ClinicalTrials.gov registry entry for NCT07075406 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Luspatercept is the first listed.

NCT07075406 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07075406 about?

NCT07075406 is a clinical study titled "A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept". The purpose of this study is to understand the treatment use of luspatercept in adults diagnosed with lower-risk myelodysplastic syndromes

What is the current status of trial NCT07075406?

This trial is currently completed. The enrollment target is 250 participants. The study started on 2024-11-01. Estimated completion is 2025-08-01.

What interventions are being tested in trial NCT07075406?

The interventions under investigation include: Luspatercept (DRUG).

Who is sponsoring clinical trial NCT07075406?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.